Company / Capital Expenditures
Ginkgo Bioworks Holdings, Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$7.7M
FY2025
5-year range
$7.7M / $62.5M
FY2021-FY2025
Trend
-87.7%
vs FY2024
Sector context
#63 of 192
Health Care
What the data says
At $8M, Ginkgo Bioworks Holdings, Inc.'s capital expenditures ranks #63 of 192 in the Health Care sector. Capital Expenditures has fluctuated over the past 7 years, ranging from $8M in FY2025 to $63M in FY2024.
Based on SEC 10-K filings.
$8M in FY2025 with a 5-year CAGR of -33.2%.
Declined from $41M to $8M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -47.3%
- 5-Year CAGR
- -33.2%
- 10-Year CAGR
- -
Sector benchmark
#63 of 192 in Health CareTop 33% of 192This company $7.7M Sector average $118.6M
▼
-93.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -33.2%, indicating a declining trend.
- In FY2025, capital expenditures decreased 87.7% year-over-year.
- Ranks #63 out of 192 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.7M | -87.7% |
| FY2024 | $62.5M | +53.3% |
| FY2023 | $40.8M | -21.9% |
| FY2022 | $52.3M | -7.5% |
| FY2021 | $56.5M | -2.2% |
| FY2020 | $57.8M | +160.2% |
| FY2019 | $22.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026